$36.61
+2.76 (+8.15%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where TECX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 7 tracked-famous managers (D. E. Shaw & Co., Inc., MARSHALL WACE, LLP, MILLENNIUM MANAGEMENT LLC, Squarepoint Ops LLC, CITADEL ADVISORS LLC, +2 more) · FINRA short interest 10.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)NCT06616974Mean change from baseline in Pulmonary Vascular Resistance (PVR) in participants with a combined pre- and post-capillary pulmonary hypertension (CpcPH).Randomized · Double-masked · Treatment | Phase 2 | Active, not recruiting | Drug: TX000045- Dose A, TX000045- Dose B, Placebo | Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction | 191 | 2026-11-24 | in 97 d | 2026-07-07 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19